About VasoGenix

VasoGenix Pharmaceuticals, Inc., is developing intravenous (IV) and controlled release drug treatments for addressing Heart Failure ("HF") and other cardiac diseases in order to reduce the recurrence of these diseases and their resulting hospital and medical costs. VasoGenix is initially focusing on a major unmet critical need in Acute Decompensated Heart Failure ("ADHF"), when the symptoms of HF become severe enough to require hospitalization.

Heart Failure ("HF"), is the most common reason for hospitalization among the aged, affects five million people with 550,000 new patients annually, and is the largest medical expense. It is responsible for 250,000 deaths annually, more than any other disease, and is responsible for the majority of deaths among people over 65. Each year, HF is the reason for over 12 million doctor office visits and around 1 million hospital admissions. ADHF is the single most expensive medical expense and about 50% of ADHF patients are readmitted within 90 days. VasoGenix believes that its product will lower the ADHF readmittance rate while providing enhanced health and financial benefits over existing therapies.

The Company's technology combines a potent drug and an established drug delivery system. The drug is based on human alpha Calcitonin Gene Related Peptide ("CGRP") and the Company's synthetic analogs. CGRP is the body's natural choice when combating the damage caused by heart failure and heart attack. It is different from other drug treatments as it is a single drug that provides multiple mechanisms to treat heart failure and other cardiac diseases. Current HF therapy requires a cocktail of drugs to manage HF symptoms and often leads to drug intolerance. Our drig therapy will augment the current standard of care, potentially reducing episodes of drug intolerance of several drug classes. No other existing or potential drug provides the combined potential advantages of improving blood circulation and diuresis, reducing inflammation of the heart muscles, and is readily accepted by the body because it is natural to it. The drug will be administered by IV for inpatient hospital use, and by a biodegradable controlled release system for outpatient treatment.

VasoGenix is in the final stages of completing its preclinical testing of a selected analog for the treatment of ADHF. When completed, the Company will seek Investigational New Drug ("IND") approval from the FDA for clinical evaluation in Phase I and II trials at the Cleveland Clinic. The Company's Clinical Research Steering Committee ("Committee"), established in conjunction with the Cleveland Clinic ("Clinic"), has guided the Company's clinical process and the Clinic has developed clinical protocols to evaluate the drug in human heart failure patients.

Because of CGRP's existing clinical and safety data, the Committee recognized that CGRP matched up well as a treatment for HF and in particular, ADHF. The unique profile of the Company's product has the potential to enhanced patient quality of life, reduce hospital length of stay and readmission rates, lower medical and hospital expenses, and provide significant market potential. The Committee has identified discernable clinical end points and milestones which it believes should provide a path to commercial success.